PubMed Health⌕ Search

PubMed · 11523385

Using Bayesian inference to perform meta-analysis.

Abstract

Bayesian modeling offers an elegant approach to meta-analysis that efficiently incorporates all sources of variability and relevant quantifiable external information. It provides a more informative summary of the likely value of parameters after observing the data than do non-Bayesian approaches. This leads to direct probabilistic inference about model parameters such as the average treatment effect, the between-study variance, and individual study treatment effects. The latter are weighted averages of the common mean and individual study means with weights reflecting the amount of information provided by each study relative to the others. Homogeneity among these posterior study estimates indicates that pooling these studies is appropriate; heterogeneity suggests that some cause of between-study variation should be explored. The author describes the construction of such models and shows how to use them to estimate a common mean and regression slopes. Two examples illustrate the additional inferences available with the Bayesian methodology.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C H Schmid. 2001. Using Bayesian inference to perform meta-analysis.. https://doi.org/10.1177/01632780122034867

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Regression analysis based on pairwise ordering of patients' clinical histories.

When a medical treatment influences a variety of outcomes, describing the global effect of treatment can be difficult. Traditional approaches specify how treatment affects each separate outcome. This can be done with separate models for each outcome, or by using a combined multivariate model. Describing the overall effect of a treatment thus requires combining these separate effects in some fashion and can be difficult to explain. In this paper, I specify a regression model for use with multiple outcomes where the outcome histories for each pair of patients are ranked. Pairs of patients with different lengths of follow-up are evaluated solely over the common follow-up interval. The logit of the probability that the outcome for patient i is better than that of patient j is assumed to depend on a linear function of the difference of the covariate vectors (for example, treatment indicators) for persons i and j. Thus covariates directly affect the entire clinical history, rather than directly affecting specific outcomes that comprise the history. The idea is that ranking outcomes is more relevant and interpretable than statistically combining separate effects. An estimating equations approach for estimation is described and an example of a clinical trial involving patients with heart failure is provided.

Angiotensin-Converting Enzyme Inhibitors↗

Liquid chromatography-mass spectrometry method for determination of ramipril and its active metabolite ramiprilat in human plasma.

A fast and robust liquid chromatography-mass spectrometry (LC-MS-MS) method has been developed for simultaneous quantitation of the angiotensin-converting enzyme (ACE) inhibitor, ramipril and its metabolite ramiprilat in human plasma. The method involves a solid-phase extraction from plasma, simple isocratic chromatography conditions and mass spectrometric detection that enables a detection limit at sub-nanogram levels. The proposed method has been validated with a linear range of 0.5-250 ng/ml for both ramipril and ramiprilat. The overall recoveries for ramipril and ramiprilat were 88.7 and 101.8%, respectively.

Angiotensin-Converting Enzyme Inhibitors↗